Sivik Global Healthcare’s Puma Biotechnology PBYI Stock Holding History

Sivik Global Healthcare’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-40,000	Closed	-$1.55M	–	66
2019 Q1	$1.55M	Buy	+40,000	New	+$1.22M	0.57%	55
2018 Q3	–	Sell	-20,000	Closed	-$1.18M	–	66
2018 Q2	$1.18M	Sell	20,000 -5,000	-20%	-$290K	0.45%	58
2018 Q1	$1.7M	Sell	25,000 -10,000	-29%	-$749K	0.79%	53
2017 Q4	$3.46M	Buy	35,000 +15,000	+75%	+$1.68M	1.28%	35
2017 Q3	$2.4M	Hold	20,000	–	–	0.81%	48
2017 Q2	$1.75M	Sell	20,000 -10,000	-33%	-$559K	0.64%	54
2017 Q1	$1.12M	Hold	30,000	–	–	0.52%	55
2016 Q4	$921K	Buy	+30,000	New	+$1.3M	0.44%	51

Other funds holding PBYI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Sivik Global Healthcare's PBYI Position: Q2 2019 in Review

Sivik Global Healthcare sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 40,000 shares — an estimated $1.55M sold.

Sivik Global Healthcare first reported a position in PBYI in Q4 2016 and held it in 8 quarters. The position peaked at $3.46M in Q4 2017. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

Sivik Global Healthcare reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
Sivik Global Healthcare sold 40,000 Puma Biotechnology shares in Q2 2019, an estimated $1.55M.
Sivik Global Healthcare first reported a position in Puma Biotechnology in Q4 2016 and held it in 8 quarters.
Sivik Global Healthcare's Puma Biotechnology position peaked at $3.46M in Q4 2017.
139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Sivik Global Healthcare's 13F filing for Q2 2019, filed 14 Aug 2019.